Lack of global regulatory coordination for cancer clinical trials costs 1.5 million lives a year despite therapies being available
prnewswire.com
business
2022-10-18 15:55:00

The Bloomberg New Economy International Cancer Coalition says Pembrolizumab and Enzalutamide could save millions of lives in Japan, the European Union (EU), Brazil, Canada, India, and China if patients were able to be treated with the drugs
NEW YORK, Oct. 18, 2022 /PRNewswire/ -- A new study by members of the Bloomberg New Economy International Cancer Coalition (the Coalition) says that at least 1.5 million deaths (representing 20 percent of global cancer deaths) from cancer could be avoided each year if international regulations around patient trials were more standardized and people placed on live saving treatment such as Pembrolizumab and Enzalutamide.
